Ergomed plc Board Changes (9928W)
29 Abril 2021 - 1:00AM
UK Regulatory
TIDMERGO
RNS Number : 9928W
Ergomed plc
29 April 2021
PRESS RELEASE
Board Changes
Dr. Llew Keltner appointed as Non-Executive Director
Guildford, UK - 29 April 2021: Ergomed plc (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry, today
announces that Dr. Llew Keltner, M.D., Ph.D., will join the Board
as a Non-Executive Director with immediate effect. The Company also
announces that Non-Executive Director, Ian Johnson, is stepping
down from the Ergomed Board to focus on his other Board roles.
Dr. Keltner brings over 30 years of experience across the life
sciences sector, holding various senior positions with a particular
focus on oncology and rare diseases. He has extensive experience of
public and private financings, M&A, the formation of strategic
partnerships and numerous transactions in the CRO, biotech and
pharma sectors. While Chairman of Raptor Pharmaceuticals Inc., a US
rare disease company, he led multiple financing rounds, product
launches and the eventual sale of the Company to Horizon
Pharmaceuticals in 2016. He was also a member of the Board of
Mannkind Corporation through its successful Nasdaq listing, and
Immunovaccine Inc. through several successful fundraises.
Dr. Keltner holds the positions of Associate Professor at Case
Western Reserve School of Medicine, and Director and Lecturer in
Bioethics at Columbia School of Medicine, as well as authoring
numerous research papers. He is currently on the Scientific
Advisory Boards of several life sciences companies across the
United States. He holds an MD and a PhD in Biomedical Informatics,
both from Case Western Reserve University in Cleveland.
Dr Miroslav Reljanović, Executive Chairman of Ergomed,
commented: "Llew's outstanding track record in the life sciences
industry, with particular focus in oncology and rare disease in the
US and globally, will be an invaluable asset for Ergomed. This
experience, together with his strong links to the US pharmaceutical
and investment communities, are fully aligned with the Company's
strategy to continue our expansion in the US and build our global
specialist leadership position. Llew will be a great addition to
Ergomed's Board and on behalf of the Board, I warmly welcome him to
his new role.
"I would also like to thank Ian for his contribution and support
of Ergomed throughout his time on the Board. We wish him all the
best for the future."
Dr Llew Keltner said: "Having seen the success and rapid rate of
growth at Ergomed, it is hugely exciting to be joining the team.
The growth in both the CRO business and PrimeVigilance has been
impressive to watch from outside and the addition of two US
acquisitions has transformed the company's presence and
capabilities in the US market. I am looking forward to working with
the Board and contributing my expertise in life sciences and US
investor relations as the Company continues on its high growth
trajectory and becomes a global leader in its chosen markets."
Dr Llew Keltner, aged 71, holds or has held directorships in the
five years preceding his appointment at Ergomed as follows:
Current Directorships Previous Directorships
YK Bio LLC Raptor Pharmaceuticals Inc
---------------------------
Infostat Systems Inc
---------------------------
BioQ Pharma
---------------------------
Light Sciences Oncology
---------------------------
EPISTAT
---------------------------
Surgeon Training International,
LLC
---------------------------
Vesselon Inc
---------------------------
OncoSCAR
---------------------------
Save as disclosed above there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive
Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260
1000
Freddie Barnfield / Matthew O'Dowd
(Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications Tel: +44 (0) 20 3709
- for UK enquiries 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray / Olivia Manser
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO), and an internationally recognised specialist expertise in
orphan drug development, under PSR. For further information, visit:
http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFFFIFSRITFIL
(END) Dow Jones Newswires
April 29, 2021 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
